Carna Biosciences, Inc. announced that it has entered into agreement with new investor AthosAsiaEventDrivenMasterFund to issue 900,000 common shares at an issue price of ¥402.3 per share for the gross proceeds of ¥362,070,000 on May 15, 2024. The transaction has been approved by shareholders of the company and is expected to close on May 31, 2024. The company disclosed the issue expenses of ¥23,500,000 and the net proceeds of the transaction is ¥338,570,000.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
385 JPY | +0.52% |
|
+1.58% | -26.25% |
1st Jan change | Capi. | |
---|---|---|
-26.25% | 43.28M | |
+38.36% | 52.73B | |
+39.50% | 39B | |
-8.63% | 38.52B | |
+25.46% | 30.38B | |
-11.17% | 26.39B | |
+11.44% | 26.08B | |
+45.09% | 14.15B | |
+32.93% | 12.6B | |
-5.30% | 11.51B |
- Stock Market
- Equities
- 4572 Stock
- News Carna Biosciences, Inc.
- Carna Biosciences, Inc. announced that it expects to receive ¥362.07 million in funding from Athos Capital Limited